Rallybio Corporation (RLYB)

Rallybio announced a one-for-eight reverse stock split on February 3, 2026. The company reported a net income of $16.0 million in Q3 2025. Dosing of the first cohort in the Phase 1 study for RLYB116 was completed on September 25, 2025. Rallybio received a $12.5 million equity milestone payment from Recursion on September 3, 2025. The company reported a net loss of $9.7 million in Q2 2025 and discontinued the RLYB212 program on August 7, 2025. Rallybio sold its interest in the REV102 program on July 8, 2025. Dosing in the RLYB116 Phase 1 study was initiated on June 12, 2025.

There is no information available regarding demand seasonality for Rallybio Corp.'s products and services, as its product candidates are still in development and not yet commercially available.

Rallybio Corp. is a clinical-stage biotechnology company focused on discovering and developing therapies for severe and rare diseases, particularly rare genetic and immunological disorders. Its pipeline includes RLYB212 (discontinued), RLYB114, RLYB116, RLYB331/RLYB332, and REV102 (sold to Recursion Pharmaceuticals). RLYB212 development was discontinued due to its inability to achieve required target concentrations for efficacy in Phase 2 trials. RLYB114 is in preclinical development for complement-mediated ophthalmic diseases. RLYB116 is a C5 inhibitor for diseases of complement dysregulation, with a Phase 1 study underway. RLYB331 is for severe anemia with ineffective erythropoiesis and iron overload, and RLYB332 is for diseases of iron overload. Rallybio sold its interest in REV102 to Recursion Pharmaceuticals.

Rallybio is headquartered in New Haven, Connecticut, US. Its operations are primarily focused on research and development.

Direct information about Rallybio Corp.'s brand reputation is not available. Its reputation is influenced by clinical trial progress, financial stability, and strategic partnerships. The discontinuation of RLYB212, advancement of RLYB116, Q3 2025 financial results, and the reverse stock split indirectly impact its reputation.

Rallybio Corporation has 53 institutional owners and shareholders holding a total of 29,940,621 shares. Major institutional shareholders include Viking Global Investors Lp, Johnson & Johnson, 5AM Venture Management, LLC, New Leaf Venture Partners, L.L.C., and Tpg Gp A, Llc. Institutional ownership accounts for approximately 68.89% of the company, while individual ownership is around 4.12%.